Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04897269
Other study ID # 656/BVTD-HDDD
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 20, 2021
Est. completion date June 20, 2024

Study information

Verified date December 2023
Source Tu Du Hospital
Contact Chau TM Le, PhD
Phone +84908429006
Email dr.lethiminhchau@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to compare clinical pregnancy rates between two groups of women who have progesterone levels below 10 ng/mL on the day of frozen embryo transfer: group 1 (vaginal micronized progesterone supplemented with progesterone intramuscular 50 mg per day) and group 2 (vaginal micronized progesterone with no supplementation)


Description:

Trial Design: Single center, longitudinal, randomized, interventional, controlled, pharmacological study, enrolling women attending clinical Centers of medically assisted reproduction (ART). The study protocol consists in the record of all the diagnostic and clinical outcome parameters, according to clinical practice, for the following patient cohorts: - The patients who are undergoing frozen embryo transfers with blastocyst or cleavage stage embryos and have progesterone levels below 10 ng/mL on the day of embryo transfer - Study groups - Group supplemented with progesterone intramuscular 50 mg per day until the day of beta-hcg testing (Intervention group); - Group with no supplementation (Control group). - Endometrial cycle is started with estradiol valerate dose of 4 mg to 8 mg per day, the patients then are appointed to have ultrasound scan of their endometrium every 3 to 7 days and the dose of estradiol may be increased to 16 mg per day maximum depends on the thickness of endometrium; when their endometrium reach 8 mm or higher and duration of endometrial preparation is ≥ 12 days, the embryo transfer will be planned and transvaginal progesterone are prescribed according to the day of transfer. - If this is the first cycle of embryo transfer and she is < 35 years of age, 1 grade 1 embryo is transferred, otherwise 2 embryos are transferred. - In the morning of embryo-transferred day, all patients will have their blood tested for progesterone levels, if their levels below 10 ng/mL, they will be recruited into the study and randomized into two groups. - In the study group, the patients will be prescribed with intramuscular progesterone supplemetation 50 mg + 800mg vaginal micronized progesterone per day for 14 days, until the day of beta-hcg testing. - In the control group, the patients will continue their regular medications (800mg vaginal micronized progesterone per day) until the day of beta-hcg testing without any progesterone supplementation. - If the beta-hcg test is positive, the patients will be continued their prescriptions depending on study or control group as mentioned above till 7 weeks of pregnancy when the fetal heart can be confirmed, then the patients will be followed up till 11 - 12 weeks of pregnancy


Recruitment information / eligibility

Status Recruiting
Enrollment 824
Est. completion date June 20, 2024
Est. primary completion date May 20, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Patients undergone ART with frozen embryo transfer, blastocyst or cleavaged stage embryo transfer, from 18-45 years of age - Normal BMI - HRT for Endometrial preparation in FET cycles Exclusion Criteria: - Oocyte donor cycles - Surrogacy - IVM - PGT - Abnormal Uterine (firbroids 0 -> 3 according to FIGO classification, polyp, adenomyosis, congenital malformation) - Uterus fibroids type 4,5 (Figo classification) > 4cm - History of recurrent implantation failure - Endometrial thickness <7mm on the day of ET - Cesarean scar defect (isthmocele)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Progesterone supplementation
This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer

Locations

Country Name City State
Vietnam Department of Infertility of Tu Du hospital Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
Tu Du Hospital

Country where clinical trial is conducted

Vietnam, 

References & Publications (4)

Cedrin-Durnerin I, Isnard T, Mahdjoub S, Sonigo C, Seroka A, Comtet M, Herbemont C, Sifer C, Grynberg M. Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reprod Biomed Online. 201 — View Citation

Gaggiotti-Marre S, Martinez F, Coll L, Garcia S, Alvarez M, Parriego M, Barri PN, Polyzos N, Coroleu B. Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates. Gynecol — View Citation

Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective st — View Citation

Volovsky M, Pakes C, Rozen G, Polyakov A. Do serum progesterone levels on day of embryo transfer influence pregnancy outcomes in artificial frozen-thaw cycles? J Assist Reprod Genet. 2020 May;37(5):1129-1135. doi: 10.1007/s10815-020-01713-w. Epub 2020 Feb — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Ongoing pregnancy rate defined as the pregnancy completed 11 - 14 weeks of gestation and having vital fetus week 11 - 14 of pregnancy
Secondary implantation rate the percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period 3 weeks after embryo transfer
Secondary Pregnancy rate beta-hCG test is positive 2 weeks after embryo transfer
Secondary clinical pregnancy rate pregnancy when fetal heart can be confirmed 3 weeks after embryo transfer
See also
  Status Clinical Trial Phase
Completed NCT05113238 - Oocyte Activation: Revised or Initial AGT Technique, Which is Better?! A Sibling-oocytes-split Design N/A
Completed NCT05113225 - Sperm Micro-swim up Technique; Process and Select in the Same Dish: a Sibling-oocyte-split Design N/A
Completed NCT03881072 - Evaluating the Endometrial Receptivity of FET Patient by Ultrasounicelastography N/A
Completed NCT02190422 - Effect of Assisted Reproductive Technology on Cardiac Development in Childhood Assessed by Echocardiography N/A
Recruiting NCT06238570 - Validation of Donor Oocytes Semi-automated Vitrification N/A
Recruiting NCT03756857 - Does the Embryo Transfer Technique Affect the Success of in Vitro Fertilization? N/A
Terminated NCT03386227 - Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT N/A
Completed NCT02171884 - Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans
Not yet recruiting NCT05164029 - The Clinical Cohort Study of Reproductive Health
Active, not recruiting NCT05404464 - Construction of CITIC Xiangya Assisted Reproduction Data Repository
Active, not recruiting NCT02109900 - Prognostic Value of Progesterone on Oocyte Retrieval Day for In Vitro Fertilization Outcome N/A
Active, not recruiting NCT04741295 - Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome N/A
Not yet recruiting NCT05738382 - Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures Phase 2
Withdrawn NCT02520869 - Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction Treatment Phase 2/Phase 3